BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia

NCT ID: NCT00074048

Last Updated: 2010-06-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2003-10-31
• Study Completion Date: 2008-07-31

Brief Summary

RATIONALE: The BL22 immunotoxin can locate tumor cells and kill them without harming normal cells. This may be an effective treatment for hairy cell leukemia that has not responded to treatment with cladribine.

PURPOSE: This phase II trial is studying BL22 immunotoxin to see how well it works in treating patients previously treated with cladribine for hairy cell leukemia.

Detailed Description

OBJECTIVES:

Primary

• Determine the response rate in patients with cladribine-resistant hairy cell leukemia treated with BL22 immunotoxin.

Secondary

• Determine the response duration in patients treated with this drug.
• Determine the safety of this drug in these patients.
• Determine the pharmacokinetics of this drug in these patients.
• Correlate BL22 blood levels and toxicity of this drug with the development of neutralizing antibodies in these patients.

OUTLINE: Patients receive BL22 immunotoxin IV over 30 minutes on days 1, 3, and 5 followed by rest.

Patients are then evaluated at 8 weeks. Patients achieving complete hematologic remission are followed. All other patients continue to receive BL22 immunotoxin as above on days 1, 3, and 5. Treatment repeats every 4 weeks for up to a total of 16 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR without minimal residual disease (MRD) receive 2 courses beyond CR. Patients achieving CR with MRD receive 4 courses beyond CR.

Patients are followed every 4 months for 1 year, every 6 months for 1 year, and then annually thereafter.

PROJECTED ACCRUAL: A total of 36 patients will be accrued for this study within 3 years.

Conditions

Leukemia

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

1

BL22 immunotoxin

Group Type: EXPERIMENTAL

BL22

Intervention Type: DRUG

Dosing via IV on Days 1,3, and 5.

Interventions

BL22

Dosing via IV on Days 1,3, and 5.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed hairy cell leukemia
• CD22-positive disease by fluorescence-activated cell sorting with anti-CD22 antibody
• Meets at least 1 of the following indications for treatment:

• Absolute neutrophil count less than 1,000/mm^3
• Hemoglobin less than 10 g/dL
• Platelet count less than 100,000/mm^3
• Absolute lymphocyte count greater than 20,000/mm^3
• Symptomatic splenomegaly
• Meets 1 of the following response criteria:

• No response
• Complete response (CR) or partial response (PR) less than 2 years in duration after the last course of prior cladribine
• CR or PR less than 4 years in duration after a second or later course of prior cladribine

PATIENT CHARACTERISTICS:

Age

• 18 and over

Performance status

• ECOG 0-2

Life expectancy

• Not specified

Hematopoietic

• See Disease Characteristics

Hepatic

• AST and ALT no greater than 2.5 times upper limit of normal (ULN)
• Bilirubin no greater than 2.2 mg/dL
• Albumin at least 3.0 g/dL

Renal

• Creatinine no greater than 1.4 mg/dL OR
• Creatinine clearance at least 50 mL/min

Cardiovascular

• No symptomatic congestive heart failure
• No unstable angina pectoris
• No cardiac arrhythmia

Other

• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No serum that neutralizes more than 75% of the activity of 1 µg/mL of BL22 immunotoxin using a bioassay
• No ongoing or active infection
• No psychiatric illness or social situation that would preclude study compliance
• No other concurrent uncontrolled illness that would preclude study participation
• Understand and give informed consent

PRIOR CONCURRENT THERAPY:

Biologic therapy

• No prior BL22 immunotoxin
• More than 12 weeks since prior monoclonal antibody therapy

Chemotherapy

• See Disease Characteristics
• More than 4 weeks since prior systemic cytotoxic chemotherapy

Endocrine therapy

• More than 4 weeks since prior systemic steroids (except stable doses of prednisone no greater than 20 mg/day)

Radiotherapy

• Not specified

Surgery

• Not specified

Other

• No other concurrent investigational agents

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

MedImmune LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

MedImmune Inc.

Principal Investigators

Robert Kreitman, MD

Role: STUDY_CHAIR

National Cancer Institute (NCI)

Locations

Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office

Bethesda, Maryland, United States

Countries

United States

References

Matsushita K, Margulies I, Onda M, Nagata S, Stetler-Stevenson M, Kreitman RJ. Soluble CD22 as a tumor marker for hairy cell leukemia. Blood. 2008 Sep 15;112(6):2272-7. doi: 10.1182/blood-2008-01-131987. Epub 2008 Jul 2.

Reference Type: DERIVED

PMID: 18596230 (View on PubMed)

Other Identifiers

NCI-04-C-0014

Identifier Type: -

Identifier Source: secondary_id

NCI-6048

Identifier Type: -

Identifier Source: secondary_id

CDR0000341680

Identifier Type: -

Identifier Source: org_study_id

NCT00071318

Identifier Type: -

Identifier Source: nct_alias